E.U. Court Advisor Rejects Bid To Close Drug Loophole

Law360, New York (January 23, 2007, 12:00 AM EST) -- A senior legal adviser to Europe's highest court has tossed a bid by pharmaceutical companies to close a legal loophole that allowed a Portuguese generic drug maker to produce a copycat version of one of Merck & Co.'s blood-pressure drugs whose 15-year patent protection had expired.

Under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, drug originators enjoy the right to a 20-year monopoly on their inventions. (The European Union signed on to that agreement in 1994.)

Before TRIPS, many countries provided only 15 years...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.